A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth Prospects

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past three months.

See our latest analysis for Recursion Pharmaceuticals.

Recent trading has been choppy, with the 1 day share price return down 3.22% and the 30 day share price return down 14.24%, while the 1 year total shareholder return has declined 26.23%. This may indicate fading momentum as investors reassess growth potential and risk.

If you are comparing RXRX with other healthcare names using AI, it can help to scan a wider field of 34 healthcare AI stocks

With shares at US$3.01, a low value score and a wide gap to analyst targets, RXRX sits at an interesting crossroads. Is the stock trading below its underlying potential, or is the market already pricing in future growth?

Most Popular Narrative: 52.8% Overvalued

RXRX last closed at $3.01, while the most followed narrative pegs fair value closer to $1.97, framing the stock as richly priced in that view.

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off! Vikki Goodman and Najat Khan can now lead RXRX back to respectability and acceptance as a real leader in biotechnology! Once the announcements start coming in on REC-4881 going to Phase 3 and beyond this stock will skyrocket! RXRX finally has the right people in place to do their jobs correctly! Many institutions will soon be coming in with more good news to follow!!!

Read the complete narrative.

The narrative behind that fair value leans heavily on ambitious revenue expansion, improving margins and a future earnings multiple more often associated with mature, highly profitable platforms.

Result: Fair Value of $1.97 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this bullish story still hinges on uncertain clinical outcomes and a business that currently reports annual revenue of US$66.41m compared with a net loss of US$559.78m.

Find out about the key risks to this Recursion Pharmaceuticals narrative.

Another View: Discounted Cash Flow Signals Upside

While the most popular narrative sees RXRX as overvalued at a fair value of $1.97, the SWS DCF model presents a different perspective. In that view, RXRX at $3.01 is trading below an estimated future cash flow value of $9.06. This raises the question of which story investors should pay more attention to.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

With such mixed signals around RXRX, it makes sense to look at the data yourself and decide how much risk and potential reward you are comfortable with, then weigh up the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If RXRX feels uncertain, do not stop here. Broaden your watchlist with fresh ideas that match your goals and risk comfort using focused stock screens.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RXRX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com